Compare OABI & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OABI | HRZN |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | 114 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.4M | 295.1M |
| IPO Year | N/A | N/A |
| Metric | OABI | HRZN |
|---|---|---|
| Price | $1.70 | $4.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | $6.67 | ★ $6.80 |
| AVG Volume (30 Days) | 272.5K | ★ 1.4M |
| Earning Date | 03-04-2026 | 03-03-2026 |
| Dividend Yield | N/A | ★ 32.20% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $52.42 | $16.70 |
| Revenue Next Year | $64.69 | $22.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $4.00 |
| 52 Week High | $2.49 | $9.52 |
| Indicator | OABI | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 29.57 |
| Support Level | $1.51 | $4.00 |
| Resistance Level | $1.75 | $6.77 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 5.13 | 28.57 |
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.